News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
SUBSCRIBE
Menu
SUBSCRIBE
Show Search
News
Drug Development
FDA
Drug Delivery
Deals
Business
Policy
Cell and Gene Therapy
Weight Loss
Rare Disease
Cancer
Job Trends
Artificial Intelligence
NextGen: Top Start Ups to Watch
Podcasts
Reports
Webinars
Press Releases
All News & Releases
Insights
Jobs
Career Advice
Companies
Hotbeds
More
Best Places to Work
Employer Resources
Post Jobs
Talent Solutions
Advertise
Submit a Press Release
Search Query
Submit Search
Search Results
Submit
Looking for jobs?
Search jobs
Close
695,840 Results
Type
Article (42017)
Company Profile (313)
Press Release (653510)
Section
Business (206270)
Career Advice (2040)
Deals (35598)
Drug Delivery (90)
Drug Development (81521)
Employer Resources (169)
FDA (16251)
Job Trends (14971)
News (348268)
Policy (32947)
Tag
Academia (2633)
Alliances (50103)
Alzheimer's disease (1256)
Approvals (16179)
Artificial intelligence (136)
Bankruptcy (354)
Best Places to Work (11653)
Biotechnology (227)
Breast cancer (130)
Cancer (1129)
Cardiovascular disease (101)
Career advice (1702)
Cell therapy (243)
Clinical research (64726)
Collaboration (404)
Compensation (202)
COVID-19 (2580)
C-suite (101)
Data (1149)
Diabetes (156)
Diagnostics (6197)
Earnings (85147)
Employer resources (147)
Events (110981)
Executive appointments (318)
FDA (16803)
Funding (364)
Gene therapy (183)
GLP-1 (591)
Government (4429)
Healthcare (18823)
Infectious disease (2665)
Inflammatory bowel disease (110)
Interviews (310)
IPO (16398)
Job creations (3688)
Job search strategy (1457)
Layoffs (421)
Legal (7919)
Lung cancer (175)
Manufacturing (186)
Medical device (13269)
Medtech (13274)
Mergers & acquisitions (19286)
Metabolic disorders (411)
Neuroscience (1542)
NextGen Class of 2024 (6591)
Non-profit (4524)
Northern California (1512)
Obesity (236)
Opinion (189)
Patents (106)
People (57085)
Phase I (20148)
Phase II (28486)
Phase III (21259)
Pipeline (465)
Postmarket research (2572)
Preclinical (8647)
Radiopharmaceuticals (237)
Rare diseases (228)
Real estate (6009)
Regulatory (21902)
Research institute (2391)
Resumes & cover letters (356)
Southern California (1331)
Startups (3653)
United States (13862)
Vaccines (571)
Weight loss (170)
Date
Today (117)
Last 7 days (616)
Last 30 days (3728)
Last 365 days (36212)
2024 (33416)
2023 (40541)
2022 (51710)
2021 (56264)
2020 (54590)
2019 (47051)
2018 (35443)
2017 (32656)
2016 (32061)
2015 (38135)
2014 (31893)
2013 (26949)
2012 (29130)
2011 (29782)
2010 (27724)
Location
Africa (740)
Arizona (193)
Asia (38112)
Australia (6203)
California (3423)
Canada (1311)
China (259)
Colorado (152)
Connecticut (155)
Europe (82046)
Florida (472)
Georgia (121)
Illinois (350)
Indiana (200)
Kansas (96)
Maryland (603)
Massachusetts (2697)
Michigan (159)
Minnesota (282)
New Jersey (985)
New York (984)
North Carolina (716)
Northern California (1512)
Ohio (142)
Pennsylvania (858)
South America (1124)
Southern California (1331)
Texas (485)
Utah (92)
Washington State (372)
695,840 Results for "biolog inc".
Filters
Sort By
Relevance
Relevance
Newest
Oldest
Business
Dyadic International, Inc. and Proliant Health and Biologicals announce Recombinant Albumin Development and Commercialization Partnership
Dyadic International, Inc. (“Dyadic”) (NASDAQ: DYAI), announced today that they have entered into a development and commercialization partnership with Proliant Health and Biologicals (PHB), a leading supplier of purified proteins for the diagnostic, nutrition and cell culture markets.
June 28, 2024
·
4 min read
News
Webinar: Revolutionizing Biologics Discovery: Harnessing the Power of AI and Patent Data
This webinar explores the pivotal role of patent data in overcoming the data challenges faced by generative AI models in drug discovery, particularly for biologics. Watch now.
October 23, 2024
·
1 min read
·
BioSpace Insights
Sponsored
Sino Biological’s New Center for Bioprocessing (C4B): US-Based CRO Services
In October 2023,
Sino Biological, Inc.
opened its
Center for Bioprocessing (C4B)
in Houston, Texas. The C4B represents a considerable global expansion of the company’s contract research service capabilities.
September 9, 2024
·
3 min read
Press Releases
Aclaris Therapeutics Announces Exclusive, Global License Agreement with Biosion, Inc., adding Potential Best-in-Class Biologics Assets to Pipeline
November 18, 2024
·
6 min read
Sponsored
SignalChem Biotech, World Leader in Kinases, Is Now Part of Sino Biological
Sino Biological, Inc. has successfully concluded the acquisition of Vancouver-based Canadian biotechnology company SignalChem Biotech Inc.
July 15, 2024
·
3 min read
Pharm Country
Neurotech Pharmaceuticals, Inc. Receives Priority Review of Biologics License Application (BLA) for NT-501 (revakinagene taroretcel) as a Treatment for Macular Telangiectasia Type 2 (MacTel)
Neurotech Pharmaceuticals, Inc. announces that the U.S. Food and Drug Administration (FDA), has determined that the Biologic License Application (BLA) for NT-501, an investigational encapsulated cell therapy for the treatment of MacTel, is sufficiently complete to permit a substantive review.
June 20, 2024
·
3 min read
Approvals
AstraZeneca Wins Rare Autoimmune Indication for Asthma Biologic Fasenra
With the FDA’s approval, Fasenra will compete with GSK’s Nucala, which in December 2017 became the first biologic approved for eosinophilic granulomatosis with polyangiitis.
September 19, 2024
·
2 min read
·
Tristan Manalac
Press Releases
Eurofins CDMO Alphora Inc. Announces Construction of GMP Biologics Manufacturing Facility
September 25, 2024
·
2 min read
BIOSECURE Act
WuXi Biologics Faces Uncertain Future in the U.S. After BIOSECURE Blow
WuXi AppTec looks to unload its Philadelphia manufacturing sites and WuXi Biologics slows its rapid expansion in the U.S. as the companies await the Senate’s review of the BIOSECURE Act that threatens to cut them off from U.S. biopharma.
October 8, 2024
·
5 min read
·
Ben Hargreaves
Axogen Inc. Initiates Rolling Submission of Biologics License Application to U.S. Food and Drug Administration (FDA) for Avance Nerve Graft®
Axogen, Inc. is pleased to announce that it has initiated the rolling submission process with the U.S. Food and Drug Administration for a Biologics License Application (BLA) for licensure of Avance Nerve Graft ® on May 15, 2024.
May 16, 2024
·
7 min read
1 of 69,584
Next
